Skip to main content

Chronic Obstructive Pulmonary Disease clinical trials at UC Davis
2 research studies open to eligible people

  • A Study of the Safety and Effectiveness of Experimental Inhaled Treprostinil For Pulmonary Hypertension due to COPD

    open to eligible people ages 18 years and up

    This is a multicenter, randomized, double-blind, placebo-controlled, 30-week, adaptive cross-over study, with a Treatment Period of approximately 26 weeks under the Original Design or, if applicable, a 17-week parallel study, with a Treatment Period of approximately 14 weeks under the Contingent Design.

    Santa Barbara, California and other locations

  • Experimental Treatment With the "Hemolung" for Patients With COPD Hospitalized for Sudden and Severe Breathing Difficulty

    “This study will test the good and bad effects of using a new medical device called the Hemolung for patients with COPD.”

    open to eligible people ages 22 years and up

    This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require respiratory support due to an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD). It is hypothesized that the Hemolung RAS can be safely used to avoid or reduce time on invasive mechanical ventilation compared to COPD patients treated with standard-of-care mechanical ventilation alone. Eligible patients will be randomized to receive lung support with either the Hemolung RAS plus standard-of-care mechanical ventilation, or standard-of-care mechanical ventilation alone.

    Sacramento, California and other locations

Last updated: